drugset / Trial / NCT00402532
Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Everolimus is effective in the treatment and prevention of chronic graft dysfunction and chronic graft rejection after lung transplantation.
Timeline
- Start
- 2005-03
- Primary completion
- 2011-11
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Everolimus | Small molecule | 0.75 mg | — |
| Comparator | Mycophenolate Mofetil | Small molecule | 500 mg | Intravenous |
Indications
No indication recorded.